Angela L. L.
- Country
- Spain
- Department
- Servicio de Oncología Médica
Research Overview
- Phase III Study of Rilvegostomig plus Combination Chemotherapy versus Durvalumab plus Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer
- Phase III Trial of BI 764532 Plus Carboplatin and Etoposide Versus Carboplatin and Etoposide in Previously Untreated DLL3-Positive Advanced Extrapulmonary Neuroendocrine Carcinoma
- Phase 2/3 Randomized Study of Telisotuzumab Adizutecan Combined with FOLFOX versus Standard of Care in First‑Line Metastatic Pancreatic Ductal Adenocarcinoma
Data & Insights
Has run more than one trial at 126 of 283 partner sites.
Specializations
Hepatobiliary Cancer Research
Focused on investigating novel treatments for advanced hepatobiliary cancers, with particular emphasis on cholangiocarcinoma and hepatocellular carcinoma.
- Immunotherapy Applications
- Targeted Molecular Therapies
- Combined Treatment Approaches
Specializes in evaluating innovative therapeutic combinations including immunomodulators and standard chemotherapy protocols.
Pancreatic Cancer Studies
Conducts research on metastatic pancreatic ductal adenocarcinoma, exploring novel treatment modalities and combination therapies.
- Tumor Treating Fields Technology
- First-line Treatment Protocols
- Immunotherapy Combinations
Evaluates advanced therapeutic approaches including modified chemotherapy regimens and innovative treatment technologies.
Gastrointestinal Oncology
Investigates treatments for gastrointestinal cancers with a focus on neuroendocrine tumors and advanced biliary tract malignancies.
- Targeted Molecular Therapies
- Novel Drug Development
- Biomarker-Driven Treatment
Specializes in developing personalized treatment approaches based on specific molecular and genetic markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.